Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01-AE gp120

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1250-1258

  Ampol, Silawun ^a   Pattanapanyasat, Kovit ^b   Sutthent, Ruengpung ^a   Permpikul, Parichart ^a   Kantakamalakul, Wannee ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE;

ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; EPITOPES; FEMALE; FLOW CYTOMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS; VIRAL VACCINES;

EID: 84866681537     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0346     Document Type: Article

References (40)

1. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194: 1661-1671.
2. McElrath MJ, De Rosa SC, Moodie Z, et al.: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008;372:1894-1905.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
4. Forthal DN, Gilbert PB, Landucci G, and Phan T: Re-combinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596-6603.
5. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, and Rinaldo C: HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157:2168-2173.
6. Lambotte O, Ferrari G, Moog C, et al.: Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009;238:897-906.
7. Gomez-Roman VR, Patterson LJ, Venzon D, et al.: Vaccine-elicited antibodies mediate antibody-dependent cellular cy-totoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174:2185-2189.
8. Florese RH, Van Rompay KK, Aldrich K, et al.: Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006;177:4028-4036.
9. Hidajat R, Xiao P, Zhou Q, et al.: Correlation of vaccine-elicited systematic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009;83:791-801.
10. Sun Y, Asmal M, Lane S, et al.: Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 2011;85:6906-6912.
11. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-104.
12. r flow cytometric method for measuring antibody dependent cell-mediated cytotoxicity (ADCC) activity in HIV-1 infected individuals. J Immunol Methods 2006;315: 1-10.
13. Sreepian A, Srisurapanon S, Horthongkham N, et al.: Conserved neutralizing epitopes of HIV type 1 CRF01-AE against primary isolates in long-term nonprogressors. AIDS Res Hum Retroviruses 2004;20:531-542.
14. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
15. Koup RA, Pikora CA, Mazzara G, Panicali D, and Sullivan JL: Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 1991;4:215-223.
16. Baum LL: Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010;7:11-18.
17. Evans LA, Thomson-Honnebier G, Steimer K, et al.: Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS 1989;3: 273-276.
18. Gomez-Roman VR, Florese RH, Patterson LJ, et al.: A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 2006;308:53-67.
19. Stratov I, Chung A, and Kent SJ: Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82:5450-5459.
20. Pollara J, Hart L, Brewer F, et al.: High-throughput quantitative analysis of HIV-1 and SIV-1 specific ADCC-mediating antibody responses. Cytometry 2011;79A:603-612.
21. Ferrari G, Pollara J, Kozink D, et al.: A HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 confor-mational epitope mediates potent ADCC activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85:7029-7036.
22. Chung AW, Isitman G, Navis M, et al.: Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011;308:7505-7510.
23. Karasavvas N, Billings E, Rao M, et al.: The Thai phase III clinical trial (RV144) induces the generation of antibodies that target a conserved region within the V2 loop of gp120. AIDS Res Hum Retroviruses 2011;27:Abstract OA07.08 LB, p. 29.
24. Nixon DF, Broliden K, Ogg G, and Broliden PA: Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992;76:515-534.
25. HIV Molecular Immunology Database 2011: HIV Sequence Database, Los Alamos National Laboratory, Los Alamos, NM. http://www.hiv.lanl.gov/content/ immunology/index.html.
26. Niedrig M, Harthus HP, Broker M, et al.: Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J Gen Virol 1992;73: 2451-2455.
27. Thali M, Moore JP, Furman C, et al.: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
28. Walker LM, Phogat SK, Chan-Hui P-Y, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
29. Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, and Kayman SC: The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005;79:6909-6917.
30. Warrier SV, Pinter A, Honnen WJ, Girard M, Muchmore E, and Tilley SA: A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol 1994;68:4636-4642.
31. Shotton C, Arnold C, Sattentau Q, Sodroski J, and McKeat-ing JA: Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1995;69:222-230.
32. Corti D, Langedijk JPM, Hinz A, et al.: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010;5e8805:1-15.
33. Gorny MK, Moore JP, Conley AJ, et al.: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
34. Stamatatos L and Cheng-Mayer C: An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998;72:7840-7845.
35. McKeating JA, Zhang YJ, Arnold C, Frederiksson R, Fenyo EM, and Balfe P: Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. Virology 1996;220:450-460.
36. Fung SC, Sun CRY, Gordon WL, et al.: Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 1992;66:848-856.
37. Sullivan N, Thali M, Furman C, Ho DD, and Sodroski J: Effect of amino acid changes in the V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on sub-unit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993;67:3674-3679.
38. Sattentau QJ and Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185-196.
39. Evans LA, McHugh TM, Stites DP, and Levy JA: Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol 1987;138:3415-3418.
40. Gupta P, Balachandran R, Ho M, Enrico A, and Rinaido C: Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol 1989;63:2361-2365.